[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"maintenance-hemodialysis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:maintenance-hemodialysis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641194","efficacy-of-pha130-hemoadsorption-on-protein-bound-uremic-toxins-and-quality-of-life-in-kidney-failure-100641194",false,"NCT07656168","Efficacy of pHA130 Hemoadsorption on Protein-Bound Uremic Toxins and Quality of Life in Kidney Failure","A Prospective, Multicenter, Randomized Controlled Trial of HAHD With pHA130 Cartridge vs. Conventional High-Flux HD for Clearance of Protein-Bound Uremic Toxins and Quality of Life Improvement in Kidney Failure.","PHOENIX","Inclusion Criteria:\n\n* Age \\> 18 years.\n* On maintenance hemodialysis for \\> 3 months.\n* Receiving hemodialysis 3 times per week, 4 hours per session.\n* Standard Kt\u002FV ≥ 1.2.\n* Voluntarily participates and provides written informed consent.\n\nExclusion Criteria:\n\n* Known allergy to the dialyzer or hemoperfusion device.\n* Platelet count \\\u003C 60×10⁹\u002FL.\n* Serum albumin \\\u003C 30 g\u002FL.\n* 24-hour urine output \\> 200 ml.\n* Inability to achieve a blood flow rate ≥ 200 ml\u002Fmin.\n* Coagulation disorders, severe bleeding tendency, or active bleeding.\n* Pre-dialysis systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg.\n* Active malignancy.\n* Active infection, or severe, critical illness of cardiac, pulmonary, hepatic, or nervous systems.\n* Planned living-donor kidney transplant within the next 6 months.\n* Current participation in another interventional clinical study, or participation within the past 3 months in an interventional study that may interfere with the present study (e.g., fecal microbiota transplantation); or use of intestinal microecological regulators such as probiotics.\n* History of unstable angina, myocardial infarction, malignant arrhythmia, cardiac or peripheral vascular surgery, or cerebrovascular accident within the past 8 weeks.","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Patients on maintenance hemodialysis (MHD) face a high risk of cardiovascular mortality and reduced quality of life. Conventional high-flux hemodialysis (HD) is the standard of care but has limited efficacy in clearing middle-molecular and protein-bound uremic toxins (PBUTs). The accumulation of these toxins is associated with adverse long-term outcomes.\n\nThis study evaluates the efficacy and safety of the pHA130 hemoadsorption cartridge, which utilizes a modified resin for enhanced PBUT adsorption, when combined with hemodialysis (HAHD). This is a prospective, open-label, multi-center, randomized controlled trial involving 100 MHD patients. Participants will be randomized 1:1 to either the HAHD group (receiving one HAHD session using the pHA130 cartridge and two standard HD sessions weekly) or the Control group (receiving three standard HD sessions weekly).\n\nThe primary objective is to assess the reduction in serum indoxyl sulfate (IS) and p-cresol sulfate (PCS) levels from baseline to 12 months. Secondary objectives include evaluating changes in quality of life (KDQoL-SF, MMSE), the progression of coronary artery calcification (CAC), the incidence of major adverse cardiovascular events (MACEs), all-cause mortality, and safety profiles. This trial aims to determine if integrating long-term HAHD therapy can optimize blood purification strategies for the MHD population.",[27,28],"ESRD (End-Stage Renal Disease)","Maintenance Hemodialysis",[30,31,32,33,34,35],"Hemoadsorption","Protein-Bound Uremic Toxins","Indoxyl Sulfate","p-Cresyl Sulfate","Cardiovascular Events","Quality of Life","RECRUITING","2026-06-22",{"date":39,"type":40},"2026-06-25","ACTUAL",{"date":42,"type":40},"2026-06-01",{"date":44,"type":21},"2028-08",{"name":46,"class":47},"China-Japan Friendship Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100633150","ai-guided-relaxation-for-hemodialysis-anxiety-100633150","NCT07522944","AI-Guided Relaxation for Hemodialysis Anxiety","Artificial Intelligence-Guided Relaxation Interventions for Reducing Anxiety and Enhancing Coping Strategies in Patients Undergoing Hemodialysis","Inclusion Criteria:\n\nAdult patients aged 18 years or older Confirmed diagnosis of end-stage renal disease (ESRD) receiving maintenance hemodialysis for at least 3 months to ensure treatment stability Conscious, oriented, and able to communicate effectively Documented baseline anxiety at a mild-to-moderate level confirmed on initial screening using the GAD-7 or HADS prior to enrollment Adequate visual and auditory functions sufficient to interact with the AI-guided relaxation platform Willing to participate and provide written informed consent prior to enrollment\n\nExclusion Criteria:\n\nHistory of epilepsy, chronic vertigo, or seizure disorders, as AI or VR visual stimuli may trigger adverse episodes Severe cognitive impairment or diagnosed psychiatric disorders such as dementia or schizophrenia that prevent comprehension of or adherence to study instructions Acute medical complications or hemodynamic instability occurring during the dialysis session Severe visual impairment or blindness precluding use of the digital relaxation interface Skin infections or injuries on the face or head preventing comfortable use of a headset where applicable Currently enrolled in any other psychological or relaxation intervention study",{"count":57,"type":21},60,[24],"This study aims to evaluate whether a relaxation program guided by Artificial Intelligence (AI) can help reduce anxiety and improve coping mechanisms for patients receiving maintenance hemodialysis. Patients undergoing dialysis often face significant psychological stress and physical discomfort. This research uses a randomized controlled trial (RCT) with a parallel-group, pretest-posttest controlled design to compare patient well-being before and after using the AI-guided intervention.\n\nParticipants will engage with an AI system designed to provide personalized relaxation techniques during their dialysis sessions. The study uses a mixed-methods approach. Quantitative: Researchers will use standardized scales to measure changes in anxiety levels, depression, coping strategies, and perceived relaxation. Qualitative: Researchers will conduct interviews with participants to understand their personal experiences, how they engaged with the AI technology, and how it influenced their ability to manage the stress of their treatment.",[61,62,63,28,64],"Renal Insufficiency, Chronic","Anxiety","Relaxation Therapy","Stress, Psychological",[66,67,68,69,62,70,71,63,72,73,74,75,76],"Hemodialysis, Hospital","Renal Dialysis","End-Stage Renal Disease (ESRD)","Psychological Distress","Artificial Intelligence","Digital Health","Mindfulness-Based Interventions","Coping Skills","AI-Guided Intervention","Virtual Reality (VR)","Immersive Technology","2026-05-07",{"date":79,"type":40},"2026-05-12",{"date":81,"type":40},"2026-03-29",{"date":83,"type":21},"2026-05-30",{"name":85,"class":47},"Alexandria University",2,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":48},"100615326","impact-of-app-assisted-patient-management-on-the-quality-control-of-blood-purification-therapy-100615326","NCT07291154","Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy","Inclusion Criteria:\n\n* Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.\n* Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.\n* Patients who can understand and proficiently use WeChat and the \"Yueya\" mini - program used in this study.\n\nExclusion Criteria:\n\n* Patients with communication barriers or other conditions that prevent them from cooperating with the study.\n* Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.\n* Patients who are not willing to actively cooperate with the study.\n* Patients with severe liver cirrhosis, active tuberculosis and AIDS.","75 Years",{"count":95,"type":21},392,[24],"Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the \"Yueya\" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.\n\nPatients will be divided into a group receiving support via the \"Yueya\" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.",[99,28],"End Stage Renal Disease (ESRD)","2025-12-05",{"date":102,"type":40},"2025-12-18",{"date":104,"type":40},"2025-09-22",{"date":106,"type":21},"2026-12-31",{"name":108,"class":47},"Yunfeng Xia"]